logo
Plus   Neg
Share
Email

Pharma News Today (TRVN,FPRX,TTPH)

Trevena, Inc. (TRVN) on Tuesday announced that the U.S. Food and Drug Administration (FDA) has accepted the company's New Drug Application (NDA) for OLINVO (oliceridine), a moderate to severe acute pain reliever injection. The Company expects that the PDUFA date for the NDA will be in the fourth quarter of 2018.

Five Prime Therapeutics, Inc. (FPRX), a biotechnology company discovering and developing innovative immuno-oncology protein therapeutics, announced that on December 27, 2017, the company initiated dosing in the Phase 1 portion of the FIGHT Phase 1/3 clinical trial of FPA144, an isoform-selective anti-FGF receptor 2b antibody, in combination with chemotherapy in patients with previously untreated, advanced gastric or gastroesophageal cancer.

Tetraphase Pharmaceuticals, Inc. (TTPH), a clinical stage biopharmaceutical company developing novel antibiotics to treat life-threatening multidrug- resistant infections, announced that it has submitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for intravenous eravacycline for the treatment of complicated intra-abdominal infections.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
eBay Inc. has filed a lawsuit against Amazon.com Inc., accusing its e-commerce rival of illegally poaching sellers on its marketplace by infiltrating eBay's internal messaging system. The lawsuit filed by eBay on Wednesday in Santa Clara County in California, accuses Amazon of having "perpetrated a scheme to infiltrate and exploit eBay's internal member email system" over the past several years. Philip Morris International Inc. (PM) announced, for the third-quarter, reported and adjusted diluted earnings per share was $1.44, up 13.4% versus $1.27 in 2017. Excluding unfavorable currency of $0.09, adjusted diluted earnings per share up by 20.5% to $1.53 from $1.27 in 2017. On average, 13 analysts... Shares of Novartis AG were gaining around 2 percent in the morning trading in Switzerland after the drug major on Thursday lifted its fiscal 2018 net sales guidance, despite weak profit in its third quarter. Core earnings topped analysts' estimates, while net sales missed their view, despite a growth. Further, Novartis announced an agreement to buy Endocyte, a US-based biopharmaceutical company.
Follow RTT